Browsing by Author "Manzoor Ahmad Qureshi"

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Comparison of Anti VEGF and Laser Photocoagulation in Diabetic Macular Edema (DME)
    (جامعة الشيخ عبدالله البدري, 2020-03-12) Salma Mahmoud El Awad; Mosab Nouraldein Mohammed Hamad; Nuha Mohamed Fath Elrahman; Muhammad Ijaz Ahmad; Abd Elaziz Mohamed Elmadina; Manzoor Ahmad Qureshi; Adil Mousa Younis; Abrar Ahmad Bhatti
    Abstract Background: To investigate the relationship of central macular thickness measure and visual acuity in diabetic macular edema (DME) before and after treatments using Ranibizumab, Bevacizumab and laser. Materials and Methods: A comparative cross-sectional retrospective study was done in Khartoum state at Al Faisal Eye Center. Heidelberg OCT was used to measure central macular thickness and visual acuity (BCVA) was evaluated by Snellen’s chart. The data were analyzed by SPSS 20. Result: A total of 102 treated patients including both male/female were enrolled with mean age 55 ± 5.41. Paired sample t-test showed a significant difference in all types of treatments based on mean vision of treated patients. With Ranibizumab the pre and post treatment mean vision was (0.20 ± 0.16) and (0.30 ± 0.25) respectively with t (-3.2) and P value 0.002. With Bevacizumab it was (0.18 ± 0.16) and (0.37 ± 0.26) respectively with t (-6.12) P value < 0.001 and with laser it was (0.28 ± 0.20) and (0.38 ± 0.27) respectively with t (-2.8) and P value 0.008.A significant difference was found in all types of treatments regarding mean of central macular thickness of treated patients. In patients treated with Ranibizumab the pre and post treatment thickness was (403.6 ± 127) and (293.6 ± 72.7) respectively with t (5.92), with Bevacizumab it was (389.3 ± 134.2) and (276.1 ± 62.6) respectively with t (5.93) and with laser it was (370.1 ± 120.7) and (280.9 ± 64.3) respectively with t (4.67) and P value < 0.001. Conclusion: Diabetic macular edema leads to blurred vision ranging from slight blurring to noticeable vision loss and Bevacizumab showed sustained improvements in vision and retinal anatomy than Ranibizumab and laser.